Expiring patents on 2 popular prescription medications could save consumers, employers and health insurers billions of dollars per year.
The Blue Cross and Blue Shield Association, Chicago, and some of the association’s member companies are making those predictions in response to major developments in the world of generic drugs.
A generic version of Zocor, or simvastatin, a cholesterol-lowering drug has just come out, and the patent on Zoloft, a brand-name version sertraline, will expire next week.
Availability of generic versions of those 2 drugs alone will lead to dramatic changes in the prescription drug market, the Blues say.
“A switch to generic versions of Zocor and Zoloft represents a watershed event,” Dr. Allan Korn, the Blue Cross and Blue Shield Association chief medical officer, says in a statement.